Research Analysts Set Expectations for VRDN Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings estimate for Viridian Therapeutics from ($1.08) to ($1.03) per share, indicating a more optimistic outlook for the company.
• Despite recent positive revisions, the consensus full-year earnings estimate for Viridian Therapeutics remains at ($4.03) per share, with projections showing a possible return to profitability by FY2028 with earnings of $0.20 per share.
• Overall, the stock has a consensus rating of "Moderate Buy" among analysts, with an average target price of $37.00, amidst mixed ratings from various equity analysts.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for Viridian Therapeutics in a research report issued to clients and investors on Wednesday, August 6th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($1.03) per share for the quarter, up from their prior estimate of ($1.08). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics' Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($4.21) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($2.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $1.49 EPS.

A number of other research analysts have also weighed in on VRDN. Needham & Company LLC decreased their price target on shares of Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Oppenheimer boosted their price target on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. Royal Bank Of Canada lowered their target price on shares of Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. The Goldman Sachs Group upped their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $37.00.

Viridian Therapeutics Stock Performance

VRDN traded down $0.61 during midday trading on Monday, hitting $18.24. 97,898 shares of the company were exchanged, compared to its average volume of 893,792. The company's 50 day simple moving average is $16.17 and its 200 day simple moving average is $15.20. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -4.79 and a beta of 0.42. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 1-year low of $9.90 and a 1-year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same quarter in the prior year, the business earned ($0.81) earnings per share. Viridian Therapeutics's revenue was up 4.2% on a year-over-year basis.

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Amalgamated Bank boosted its stake in shares of Viridian Therapeutics by 49.7% in the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after purchasing an additional 840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock valued at $669,000 after purchasing an additional 876 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Viridian Therapeutics by 2.9% in the first quarter. SG Americas Securities LLC now owns 31,972 shares of the company's stock valued at $431,000 after buying an additional 887 shares in the last quarter. Voya Investment Management LLC grew its stake in shares of Viridian Therapeutics by 5.1% in the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock valued at $410,000 after buying an additional 1,038 shares in the last quarter. Finally, Tudor Investment Corp ET AL boosted its position in Viridian Therapeutics by 3.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock worth $735,000 after purchasing an additional 1,106 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.